Product Images Venlafaxine Hydrochloride

This is a table of drug interactions and their effects on the PK Fold Change and 90% CI Recommendation for various analytes including venlafaxine. The table suggests avoidance of concomitant use for some drugs, use with caution for others, and recommends no dose adjustment for some drugs. The table also suggests monitoring blood pressure for some drugs and clinical significance is unknown for others.*

This appears to be a list of drugs, with their interactions and recommendations for dose adjustments based on PKFold change and 90% CI. Each drug is listed with its Cmax and AUC values. The recommendations range from "Avoid concomitant use" to "No dose adjustment" and "Use with caution, monitor blood pressure." It is not clear what the reference value is, or what the purpose of this list is without further context.*

This is a table showing recommended adjustments in dosing for venlafaxine in special populations such as patients with hepatic impairment and renal impairment, based on the analyte PK fold change and 90% CI recommendations. The table also notes that there is no dose adjustment necessary for patients with CYP2D6 polymorphism, for patients over the age of 60, and for gender differences. The data in the table represents changes relative to the reference value.*

This is a medication description for Venlafaxine ER, which is an orange and white capsule with the markings V;11. The medication is a 150mg capsule that should be stored at room temperature between 20°-25°C (68°-77°F) and kept out of reach of children. It is manufactured by Annora Pharma Put. Ltd. and has an expiration date of MM/YY. The NDC number is 7133518121 04534301523487.*